RFM
VRTX icon

Royal Fund Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Royal Fund Management’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-7
Closed -$1K – 756
2019
Q4 		$1K Sell
7
-19
-73% -$3.85K ﹤0.01% 610
2019
Q3 		$4K Buy
+26
New +$4.6K ﹤0.01% 477

Other funds holding VRTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Royal Fund Management's VRTX Position: Q1 2020 in Review

Royal Fund Management sold out of Vertex Pharmaceuticals (VRTX) in Q1 2020, closing a stake of 7 shares — an estimated $1K sold.

Royal Fund Management first reported a position in VRTX in Q3 2019 and held it in 2 quarters. The position peaked at $4K in Q3 2019. 856 funds tracked by Wall St. Rank hold VRTX as of Q1 2020.

  • Royal Fund Management reported no remaining Vertex Pharmaceuticals position as of Q1 2020 after selling out during the quarter.
  • Royal Fund Management sold 7 Vertex Pharmaceuticals shares in Q1 2020, an estimated $1K.
  • Royal Fund Management first reported a position in Vertex Pharmaceuticals in Q3 2019 and held it in 2 quarters.
  • Royal Fund Management's Vertex Pharmaceuticals position peaked at $4K in Q3 2019.
  • 856 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2020.

Based on Royal Fund Management's 13F filing for Q1 2020, filed 8 May 2020.